Quidel, a developer of diagnostic solutions, has obtained CE mark approval for its Quidel molecular RSV + hMPV assay.

The assay is designed to distinguish between respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) that cause respiratory infections with very similar symptoms.

Quidel has also expanded its molecular product line with the launch of Quidel molecular RSV + hMPV assay.

The molecular product line provides PCR reagent kits for use by molecular diagnostic laboratories with their existing thermocyclers.

PCR reagents features simple transport and refrigerated storage (no freezer required), convenient workflow, a short time to result, and other benefits that favorably affect diagnostic test outcome.

The company said the RSV + hMPV assay can be batched along with Quidel molecular influenza A+B PCR assay in the same multi-well panel, as they share a common extraction protocol.